45 patents
Page 2 of 3
Utility
Humanized Bcma Antibody and Bcma-car-t Cells
27 May 21
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5.
Lijun Wu, Vita Golubovskaya
Filed: 13 Jan 21
Utility
Engineered nucleic acid-targeting nucleic acids
11 May 21
The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 11 Mar 20
Utility
Method of target cleaving using CRISPR hybrid DNA/RNA polynucleotides
27 Apr 21
The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.
Andrew Paul May, Paul Daniel Donohoue
Filed: 28 Jul 20
Utility
Engineered Cascade Components and Cascade Complexes
8 Apr 21
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides.
Peter Sean Cameron, Scott David Gradia, Sanne Eveline Klompe, Samuel Henry Sternberg, Matthew Scott Thompson
Filed: 11 Dec 20
Utility
Modified cascade ribonucleoproteins and uses thereof
23 Mar 21
A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity.
Stan Johan Jozef Brouns, John van der Oost
Filed: 26 Jun 20
Utility
Humanized BCMA antibody and BCMA-CAR-T cells
23 Feb 21
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5.
Lijun Wu, Vita Golubovskaya
Filed: 2 Sep 20
Utility
Modified Lymphocytes
6 Jan 21
Modified lymphocytes that ectopically express an endogenous gene of interest, such as a gene encoding a chemokine cell surface receptor, are described.
Katharina F.S. Stengel
Filed: 3 Dec 18
Utility
Engineered Cascade Components and Cascade Complexes
6 Jan 21
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides.
Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
Filed: 20 Sep 20
Utility
Humanized Bcma Antibody and Bcma-car-t Cells
23 Dec 20
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5.
LIJUN Wu, Vita Golubovskaya
Filed: 1 Sep 20
Utility
Modified Cascade Ribonucleoproteins and Uses Thereof
14 Oct 20
A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity.
Stan Johan Jozef Brouns, John van der Oost
Filed: 25 Jun 20
Utility
Engineered Nucleic-Acid Targeting Nucleic Acids
7 Oct 20
The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 18 Jun 20
Utility
Engineered cascade components and cascade complexes
21 Sep 20
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides.
Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
Filed: 18 Mar 20
Utility
Engineered Cascade Components and Cascade Complexes
2 Sep 20
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides.
Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
Filed: 18 Mar 20
Utility
Modified cascade ribonucleoproteins and uses thereof
13 Jul 20
A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cash which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity.
Stan Johan Jozef Brouns, John van der Oost
Filed: 27 Aug 19
Utility
Engineered nucleic-acid targeting nucleic acids
13 Jul 20
The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 17 Nov 19
Utility
Engineered Nucleic Acid-targeting Nucleic Acids
1 Jul 20
The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 10 Mar 20
Utility
Engineered cascade components and cascade complexes
23 Mar 20
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides.
Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
Filed: 27 Oct 19
Utility
Engineered nucleic acid-targeting nucleic acids
16 Mar 20
The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 17 Oct 17
Utility
Novel Crispr-associated (Cas) Protein
11 Mar 20
A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering.
Matthew Merrill Carter, Paul Daniel Donohoue
Filed: 21 Nov 19
Utility
Engineered Nucleic-Acid Targeting Nucleic Acids
4 Mar 20
The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 17 Nov 19